Click here to leave a message
Featured PeptidesPeptide ServicesCatalog Peptides
- RGDCArg-Gly-Asp-Cys is the binding motif of fibronectin to cell adhesion molecules, and can inhibit platelet aggregation and fibrinogen binding.
- Alarelin AcetateAlarelin acetate is a synthetic Gonadotrophin-releasing hormone agonist. It is the acetate form of a hypothalamic peptide. It is a potent LH-RH agonist in rats and mice. It reversibly delays sexual maturation in rats, stimulates spawning activity in fish. It could inducte ovulation and is used to treat endmometriosis. It is responsible for the secretion of gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), from the pituitary glands.
- Peptide YY (PYY), humanPeptide YY (PYY) is mainly found in gastrointestinal tract. It is believed to involve feeding behavior. It is a gut hormone that inhibits both secretin- and cholecystokinin-stimulated pancreatic secretion. This peptide is an endogenous nonselective agonist at NPY receptors.
- HIV p17 Gag (77-85)HIV-1 gag p17 protein is an attractive target for molecular intervention, because it is involved in the viral replication cycle at both the pre- and postintegration levels. In the present experiments, we targeted p17 by intracellularly expressing a cDNA encoding an Ab to p17. cDNA from a hybridoma-secreting Ab to p17 was cloned, sequenced, reconstructed as a single-chain Ab fragment (scFv), and expressed in the cytoplasm or nucleus with appropriate retention signals. The expressed scFvs had no effect on T cell growth or CD4 expression and bound specifically to HIV-1 p17. Human CD4+ Jurkat T cells that expressed scFvs and were infected with HIV-1 showed a marked reduction in virus replication compared with cells expressing vector alone. The inhibition of virus replication was more pronounced when scFvs were expressed in the cytoplasm rather than the nucleus. From these studies, we conclude that the intracellular expression of a single-chain Ab to p17 inhibits HIV replication; in addition, the degree of inhibition is related to the intracellular targeting site.
- Substance P (1-7)Substance P (SP) is an endogenous tachykinin neuropeptide that is involved in inflammatory, pain, and stress signaling; it exhibits neuroprotective, cognition enhancing, and gastrointestinal motility modulating activities. SP exhibits neuroprotective activity by decreasing expression of Kv1.4 K+ channels in transgenic animal models of Alzheimer’s disease and improving cognitive performance in the Morris water maze task. SP is the natural ligand for the neurokinin-1 (NK1) receptor. In various animal models, SP modulates opioid signaling, induces gastric mucosal protection, and inhibits retinal apoptosis. SP also prevents hyperoxia-induced lung damage, decreasing levels of malondialdehyde and increasing levels of superoxide dismutase (SOD); this activity may be regulated through SHH signaling. In melanoma cells, SP decreases levels of tyrosinase and melanin, inhibiting melanogenesis. In other cellular models, SP increases the viability and proliferation of osteoblasts and promotes gap junction intracellular communication.
- Amylin (20 - 29), humanAmylin is produced in the pancreas beta cells and coreleased with insulin. Amylin's amino acid sequence shows great homology with CGRP. Amylin has been shown to reverse insulin inhibition of hepatic gluconeogenesis and to inhibit muscle uptake of glucose.
- SomatostatinSomatostatin is an endogenous peptide noted to inhibit the release of growth hormone, insulin and glucagon. Additionally, Somatostatin Inhibits voltage-dependent calcium channels.
- Cyclo ( - RADfK - )This peptide is a negative control for the cyclo (-RGDfK-), the RGD peptide. RGD peptides are modulators of cell adhesion and are recognized by several members of the integrin family. This peptide has low affinity binding to integrin peptides.
- [Glu3] - RGES, Control for RGD PeptidesThis peptide is a control for the RGDS Fibronectin Active Fragment and other RGD-related peptides. Asp3 is replaced by Glu3 in RGDS peptide changing its properties to inhibit integrins and proteins of extracellular matrix binding.
- Cyclo ( - RGDfK)In one study where this peptide was labeled with 125I, it was found to bind specifically and with high affinity to αvβ3 receptors on neovascular blood vessel sections of different major human cancers. The integrin alpha(IIb)beta(3)-specific cyclic hexapeptide contains an Arg-Gly-Asp (RGD) sequence.
- Cyclo (RGDfC)This is a cyclic RGDfC sequence, an integrin avb3-affine peptide.
- β-Amyloid (1-20)This synthetic peptide consists of amino acids 1 to 20 of beta amyloid protein.
Publications Citing Use of Ontores Products
- Food Chemistry Volume 197, Part B, 15 April 2016, Pages 1160-1167
- Journal of Controlled Release Volume 217, 10 November 2015, Pages 138-150
- JBIC Journal of Biological Inorganic Chemistry September 2016, Volume 21, Issue 5–6, pp 683–690
- Journal of Radioanalytical and Nuclear Chemistry December 2017, Volume 314, Issue 3, pp 2201–2207
- mBio,20 September 2016,vol. 7 no. 5 e01418-16
- Biochemical and Biophysical Research Communications Volume 477, Issue 4, 2 September 2016, Pages 647-653
- Journal of Controlled Release 217 (2015) 138–150
- Journal of Radioanalytical and Nuclear Chemistry December 2017, Volume 314, Issue 3, pp 2181–2188
- Sci Rep. 2016; 6: 34269.
- Molecular & Cellular Proteomics,October 1, 2017 16, 1789-1800.
- Anal. Methods, 2015,7, 9949-9956
- Nuclear Medicine and Biology Volume 52, September 2017, Pages 1-6
- ACS Appl. Mater. Interfaces, 2015, 7 (38), pp 21442–21454
- Metallomics, 2016,8, 1266-1272
- Journal of Comparative Physiology B December 2017, Volume 187, Issue 8, pp 1155–1161
- Sensors and Actuators B: Chemical Volume 244, June 2017, Pages 1022-1030
- Med Sci Monit. 2017; 23: 3593–3602.
- BMC Microbiology (2016) 16:129
- Molecular and Cellular Biochemistry August 2015, Volume 406, Issue 1–2, pp 293–299
- JBIC Journal of Biological Inorganic Chemistry April 2015, Volume 20, Issue 3, pp 563–574
- Materials Research Bulletin Volume 94, October 2017, Pages 378-384
- OncoImmunology Volume 5, 2016 - Issue 4
- Pharmaceutical Development and Technology ,15 Dec 2016,Pages 1-9
- Biotechnology Letters June 2017, Volume 39, Issue 6, pp 897–903
- Amino Acids January 2017, Volume 49, Issue 1, pp 75–88
- Anal. Chem., 2017, 89 (15), pp 7933–7942
Copyright © 2015 Ontores Biotechnologies Inc.